Stem Cell Clinic

Evera, A Harvard Consumer Biotech Company, Brings Stem Cell Banking To You – Forbes

By Induced Pluripotent Stem Cells

Throughout the past decade, consumer biology tests have been all the rage. Companies such as 23andMe and Ancestry DNA have made their test kits accessible to every day Americans. One can screen for anomalies in their genetic code or identify their lineage. With recent advances in stem cell research, a new opportunity within the consumer biology market has appeared. Nabeel Quryshi, Michael Chen and Zeel Patel are three Harvard undergraduates who observed the unmet, rising demand of control over ones stem cells. They worked together to create Evera, the first at-home stem cell banking company. The three Harvard students are joined by the schools world-renowned biology professor, Dr. George Church. The Cambridge, Massachusetts-based company was incubated at the Harvard Innovation Lab, and has former NASA astronaut Scott Kelly as a investor.

Evera cofounders from left to right: Nabeel Quryshi, Michael Chen and Zeel Patel.

Kelly says, "I did a lot of my independent research, consulted with NASA physicians and scientists, and experts in the stem cell for cancer treatment fields. All those discussions and research indicated that this technology has merit."

Frederick Daso: What led you and your team to identify that stem cells could be potentially used to prevent neurodegenerative disease?

Nabeel Quryshi: I wouldn't single out a focus on neurodegenerative diseases. However, over the last decade, there has been a flurry of research around the use of stem cells to treat conditions such as Parkinson's, Dementia, Alzheimer's, etc. People are working on prevention, but there are two main use cases of stem cells currently. One is for treatment (replacement of damaged or lost cells), and the other is disease modeling (being able to model diseases and test the effects of new drugs completely in vitro without having to get a biopsy).

Daso: In the same ways that blood banks function, how did you manage to apply that concept to the storage of stem cells over a long time?

Quryshi: Cord blood banks and academic stem cell banks that use standardized cryopreservation protocols have been around for a while. The main innovation behind Evera was developing technology around the collection and preservation of urine-derived cells.

Daso: Why don't more mothers store their children's cord blood in stem cell banks? Is it mostly due to a price issue, or is there some other factor at play?

Quryshi: From the countless interviews we've done, it seems to be a price issue. Additionally, it's hard to make a sale around the time of birth as families have countless other things to worry about that are more immediate to the birth of a child.

Daso: What would be driving the growth of this market both now and in the future?

Quryshi: The growth of new cutting edge cell therapies is certainly further demonstrating the need for personal cell biobanking. Furthermore, the success of the direct to consumer genetic testing industry (23andMe, Ancestry, etc.) is a significant driver of growth. From the research we've conducted and the customers we have spoken to, individuals who have already taken 23andMe or another genetic test and know what they are at risk for genetically are looking for ways to take tangible action. Evera is that next step. Instead of just understanding what your future genetic risk is, Evera allows you to make a real biological investment in your future health and wellbeing. While knowing you're at risk for saying Parkinson's is excellent, being able to set aside your youngest cells so that one day you may be able to combat the effects of such a disease is terrific.

However, one should note that although the growth and technology coming from the cell therapy and stem cell therapy industry is astonishing, these are still projections. We have yet to see a fully FDA approved therapy that utilizes the specific types of stem cells we use (induced pluripotent stem cells). Nevertheless, by the time such treatments make it to the clinic, your cells will have aged significantly, and thus it makes sense to save them away now.

Daso: Could you walk me through the thought process of figuring out how to extract stem cells from urine? (From what I know, stem cells usually come from other parts of your body!)

Quryshi: Until around 2011/2012, you would have been right. However, utilizing the fantastic technology that comprised Dr. Yamanaka's 2006 Nobel Prize, scientists have been able to convert any cell in the human body to a kind of stem cell called an induced pluripotent stem cell. This cell has the capability of being able to differentiate into any cell type in the human body. We have advanced tech around the conversation of urine-derived cells to these iPSCs.

Daso: How have you designed your D2C service to ensure that a customer's DNA and associated data are not at risk?

Quryshi: We take data and privacy extremely seriously. We are well aware of the concerns people already have to D2C genetics products. To ensure the confidentiality and privacy of your data and sample, we separate your personally identifiable information from sample information and simultaneously use multiple layers of encryption and cryptography. Your sample and associated data cannot be associated with you individually. Furthermore, our facility is monitored 24/7 with top of the line security measures. We believe that your sample is your property.

Daso: What was the turning point during your undergrad to pursue this idea?

Quryshi: Having worked at 23andMe, I was able to get the lucky opportunity to be a part of arguably the world's most successful consumer genetics company. I saw first hand the benefits of providing customers with their genetic risk. Yet, I discovered that merely providing such risk predictions may not be enough led me to found Evera on the notion that tangibly investing in one's future health and wellbeing through cell banking will propel us into the age of personalized medicine.

Daso: How do you leverage your advisory board to navigate regulations and moral hazards in this space?

Quryshi: We have assembled a dream team consisting of experts in stem cell banking and cell therapy. Our co-founders and advisors comprise of professors from Harvard and Stanford, executives from companies such as Verily as well as top grad students and postdocs in stem cell biology from Harvard and Stanford. We work collaboratively to make sure we adhere to all regulations and ensure the secure preservation of our customer's cells.

If you enjoyed this article, feel free to check out my other work onLinkedInand my personal website,frederickdaso.com. Follow me on Twitter@fredsoda, on Medium@fredsoda, and on Instagram@fred_soda.

Originally posted here:
Evera, A Harvard Consumer Biotech Company, Brings Stem Cell Banking To You - Forbes

Here’s Why Fate Therapeutics Rose 18.4% in May – The Motley Fool

By Induced Pluripotent Stem Cells

What happened

Shares of Fate Therapeutics (NASDAQ:FATE) gained over 18% last month, according to data provided by S&P Global Market Intelligence. Most of the stock's gains in May can be traced to a single announcement by the cell-therapy developer.

On May 20, the development-stage company announced the U.S. Food and Drug Administration (FDA) cleared a new drug candidate to begin clinical trials. Identified as FT538, the drug candidate is the first cell therapy that has been both engineered with CRISPR gene-editing tools and derived from induced pluripotent stem cells (iPSC). The combination could lead to safer, more effective, and significantly lower-cost drug products.

Investors cheered the latest sign of progress for the early stage pipeline -- and the momentum hasn't waned. In fact, a public offering of common stock on June 9 triggered additional gains for the pharma stock. Apparently, investors are content with dilution so long as Fate Therapeutics maintains a well-funded balance sheet.

Image source: Getty Images.

Fate Therapeutics has one of the most ambitious pipelines in cell therapy, spanning 13 unique programs and multiple cell types. Until recently, investors had few tangibles to analyze, but promising (very) early-stage data and a multi-billion-dollar partnership with Johnson & Johnson subsidiary Janssen have de-risked the stock.

It might be a bit silly to get excited about a preclinical asset moving to clinical trials, but FT538 could prove to be an important bellwether for Fate Therapeutics. If researchers prove that gene-editing tools can be used with reproducible results on cells grown from master cell lines, such as iPSCs, then it would be a big step forward for the field of cell therapy. The capabilities would enable the relatively quick engineering of cell therapies, both for efficacy and safety, and allow living drug products to be manufactured at scales and costs simply not possible today.

Including cash on hand at the end of March and the expected proceeds from the stock offering on June 9, Fate Therapeutics should begin the second half of 2020 with at least $350 million in cash. That should be enough to generate results from a handful of ongoing clinical trials, but investors shouldn't forget that the company's ambitious pipeline will require many hundreds of millions of dollars to develop.

See the original post here:
Here's Why Fate Therapeutics Rose 18.4% in May - The Motley Fool

Nanion Technologies and Nexel Partner to Open a New Reference Demonstration Laboratory in South Korea – Labmate Online

By Induced Pluripotent Stem Cells

Nanion Technologies and Nexel are pleased to announce a partnership, focused on combining Nanions CardioExcyte 96 and FLEXcyte 96 cell monitoring technology with Nexels hiPSC-derived cells for demonstration purposes. Bringing together the two companies infrastructure and expertise serves to meet the growing demand for a reliable, high throughput cell monitoring technology in Asia.

The Nanion- Nexel partnership brings together profound skills in comprehensivein vitroelectrophysiology technology and development of human induced pluripotent stem cells (hiPSCs), with focus on cardiomyocytes. Under the partnership, Nexel opens a reference demonstration laboratory for Nanions systems at Nexels headquarters in Seoul, whereby both companies aim to significantly upscale support of their clients in Asia.

Dr Choong-Seong Han, CEO of Nexel, said: Nexel is proud to start this partnership with Nanion Technologies. We believe it will further build on the excellent relationship we have developed together in the last year. The Cardiosight-S cardiomyocytes have been fully validated on the CardioExcyte 96 and FLEXcyte 96 systems and our expert scientists are dedicated to provide the best demo settings as well as product experience for customers, as part of the collaboration. We hope interest in both Nanions and Nexels offerings will increase with our collaborative efforts.

Frank Henrichsen, Director of Global Sales of Nanion Technologies added: We are very eager to strengthen our position in the Asian market and especially in Korea. In Nexel, we see a valuable partner to help us develop our presence, in this case through opening their laboratories and enabling the use Nanions technology for demo purposes at their premises. Combining Nexels hiPSC-derived cardiomyocytes and cardiacin vitroassays with Nanions CardioExcyte 96 and FLEXcyte 96 systems, we are confident that our customers will get an excellent package solution for use in safety pharmacology and toxicology assays. We are also very happy that Nexel has already implemented the systems into their quality control procedure of Cardiosight-S cardiomyocytes.

Go here to see the original:
Nanion Technologies and Nexel Partner to Open a New Reference Demonstration Laboratory in South Korea - Labmate Online

Here Are a Bunch of Photos of Cops Not Wearing Masks – Futurism

By Stem Cell Doctors

At a protest in Queens, I asked a police officer why he wasnt wearing a mask.

Coronas over, he replied.

As Black Lives Matter protests against police violence and systematic racism erupted across the country, an unfortunate trend has emerged: while police often show up heavily armed and wearing riot gear, they seldom wear medical masks or other face coverings to prevent COVID-19 from spreading.

By not wearing masks, police are putting themselves and others at a greater risk of catching the coronavirus, experts told Time.

If a state, if a county, if a city is telling the general public to wear masks, Johns Hopkins health researcher Amesh Adalja told Time, then the police officers must follow that same law.

While a number of public health experts have argued that protestors are unlikely to cause a huge explosion in coronavirus infections, that assumes that everyone takes basic common-sense measures like keeping distance where possible and wearing a medical mask that keeps them from spreading pathogens.

Some cops are skipping masks entirely. Others are wearing them wrong, by pulling them down to expose their noses or mouths.

And while being outdoors likely reduces the risk of transmission, tightly clustered police and the protestors they arrest become public health hazards. Meanwhile, as of May 4, the NYPD had spent $12 million on medical masks this year alone, pointing to a major waste of time and resources given how few cops actually wore them.

I attended multiple protests and vigils throughout New York City. At all of them, the majority of police opted to skip the face mask or wear it improperly.

Videos from other protests, like this one of Austin police opening fire on a crowd of peaceful protestors, highlight that the problem of police ignoring their masks is a national issue.

Read more:
Here Are a Bunch of Photos of Cops Not Wearing Masks - Futurism

Lies and Hypocrisy: Anti-Abortion Arguments to Restrict the Abortion Pill – Ms. Magazine

By Stem Cell Doctors

The anti-abortion movement is pressing the Trump administration to rescind changes and even more severely tighten restrictions on the abortion pill. (support circle / Flickr)

The anti-abortion movement has fought a long-standing battle against access to the abortion pill. In the 1980s, they threatened to boycott drug companies developing the drug. In the 1990s, they waged a campaign to block FDA approval of the pill; although finally approved in late 2000, severe restrictions were placed on distribution of the pill by the FDA.

After research showed that a lower dosage of 200 mginstead of 600 mgwas just as effective and caused fewer side effects, and that the drug could be used safely later into pregnancyuntil 70 days instead of 49anti-abortion advocates pressured the FDA for years to maintain the higher dosage and shorter timeline for usage of the pill.

Under the Obama administration, the FDA finally approved the lower dosage and longer timeline in 2016, but today the anti-abortion movement is pressing the Trump administration to rescind those changes and even more severely tighten restrictions on the abortion pill.

Through these campaigns to suppress theusage of the abortion pill, anti-abortion advocates have spread misleading and false information about the safety and efficacy of the abortion pill.

A glaring contemporary example of this strategy is the right-wing Family Research Council (FRC)s recent report, titled The Next Abortion Battleground: Chemical Abortion.

Founded in 1983 as a division of James Dobsons religious right organization Focus on the Family, the Family Research Council is now one of the far rights most powerful advocacy groups, fighting against abortion, stem cell research and LGBTQ equality, and promoting the Judeo-Christian worldview as the basis for a just, free and stable society.

The FRCs chemical abortion report is full of lies and misrepresentations, citing discredited research and junk science. The report uses inflammatory and misleading language, and is replete with hypocritical arguments.

One way FRC tries to mislead the public is by using inflammatory and alarmist language.

For example, they use the phrase chemical abortion to make abortion pills sound dangerouswhen in fact they are very safe.

Here atMs., our team is continuing to report throughthis global health crisisdoing what we can to keep you informed andup-to-date on some of the most underreported issues of thispandemic.Weask that you consider supporting our work to bring you substantive, uniquereportingwe cant do it without you. Support our independent reporting and truth-telling for as little as $5 per month.

Throughout the report, they refer to embryos and fetuses as babies, and they describe misoprostol as a drug that yanks the baby out of the womb. They refer to medication abortion as a violent regimen. Their language is misleading and overwrought.

The FRC report repeatedly refers to the abortion industryan attempt to make doctors and other clinicians providing abortion health care sound nefarious and exploitative.

This extreme and inflammatory language demonizes people providing and having abortions. But FRC goes farther. They explicitly lie about the risks of medication abortion.

The FRC report is riddled with misrepresentations and outright lies about the safety of medication abortion. They claim that the abortion pill poses profound dangers to women. In fact, mifepristone is an extremely safe drug.

The FRC plucks from the mifepristone medication guide the rarest but most severe drug reactions and frames them as common. FRC cites discredited research and junk science, making the false claim that abortion causes depression, and then claims, without evidence, that medication abortion is uniquely traumatic to women, more so than aspiration abortion.

FRC inaccurately claims that mifepristone is subject to the FDAs drug safety programRisk Evaluation and Mitigation Strategies (REMS)because it carries such life-threatening risks. In fact, mifepristone is subject to the REMS restriction because of politics, not safety concerns. Mifepristone issix times safer than Viagrawhich the FDA does not restrict under the REMS program.

The REMS restriction means that mifepristone cannot be distributed through pharmacies like most other drugs. Instead, only doctors registered with the manufacturer can dispense the pill to their patients.

Throughout the report, the FRC inaccurately argues that removing the FDA REMS restriction would lead to the abortion pill being available over the counter, making do-it-yourself abortions the norm. In fact, in the absence of the REMS restriction, the abortion pill would be treated like most other drugsavailable at pharmacies by prescription, under the supervision of a doctor. Simply removing the FDA REMS restriction would not result in do-it-yourself abortion.

At the end of their report, the FRC calls on the FDA to strengthen restrictions on the abortion pill, prohibit telemedicine abortion and require doctors to conduct unnecessary physical examinations of patients receiving the abortion pill. These barriers would significantly decrease access to medication abortion and increase the costs.

FRC also calls for the criminal prosecution of Rebecca Gomperts of AID Access, who assists people in obtaining and using the abortion pill, as well as cracking down on online pharmacies that sell the pill.

Finally, they call for shutting down Gynuity Health Projects TelAbortion study, which allows an exception to the REMS restriction in certain states.

In fact, they are terrified of the power and control that the abortion pill puts into womens hands. They hate the way that medication abortion can avoid the obstacles and restrictions they have constructed over the last 47 years since Roe v. Wade legalized abortion in the United States.

A cheap, widely accessible abortion pill that women could obtain through the mail and take in the privacy of their own homes would mean anti-abortion extremists would lose the opportunity to harass and yell at women going into and out of clinics, terrorizing them with their abuse.

The National Womens Health Network is leading a campaign to raise awareness about the FDA restrictions on the abortion pill, pressure the FDA to lift the restrictions, and make the abortion pill more widely available. You can find resources for the campaign on their website, which they encourage people to share widely using the hashtag #MailTheAbortionPill.

Public policy must be based on medical science and genuine concern for womens healthnot on the lies, misrepresentations and hypocrisy of hate groups like the Family Research Council.

The coronavirus pandemic and the response by federal, state and local authorities is fast-moving.During this time,Ms. is keeping a focus on aspects of the crisisespecially as it impacts women and their familiesoften not reported by mainstream media.If you found this article helpful,please consider supporting our independent reporting and truth-telling for as little as $5 per month.

See the original post here:
Lies and Hypocrisy: Anti-Abortion Arguments to Restrict the Abortion Pill - Ms. Magazine

Cryo-Cell to Donate 50,000 Face Masks to OBGYN Practices and Patients Around the Country Amidst COVID-19 – PR Web

By Stem Cell Doctors

We recognize and salute the vital role that physicians and other healthcare providers play in taking care of pregnant women, especially during the COVID-19 pandemic.

OLDSMAR, Fla. (PRWEB) June 08, 2020

Cryo-Cell Internationals announcement comes on the heel of increased demand for masks and other protective measures to protect workers in the medical field. The face masks will be distributed nationwide to obstetrical and gynecological doctors and their dedicated staffs who valiantly risk their lives every day to provide healthcare to pregnant women. The delivery of masks is scheduled to begin later this week.

In addition to face mask donations, Cryo-Cell International has and will contribute other essential supplies within the medical field including face shields, hand sanitizers, and informational pieces regarding COVID-19 for practitioners and pregnant patients alike.

David Portnoy, Cryo-Cell Internationals Chairman and Co-CEO, stated, We recognize and salute the vital role that physicians and other healthcare providers play in taking care of pregnant women, especially during the COVID-19 pandemic. In support of their noble efforts, Cryo-Cell International is proud to provide essential medical items to allow them to provide the highest quality care for their patients.

Cryo-Cell International remains committed to providing clients with premier cord blood and cord tissue preservation service and aiding in the advancement of regenerative medicine. As research continues to develop in finding treatments for COVID-19 through the use of mesenchymal stem cells found in cord tissue, the company continues to help expecting parents protect what matters most through umbilical stem cell preservation. Cryo-Cell International anticipates ongoing plans to aid in financial contributions and personal protective equipment donations to help safeguard the efforts of essential workers in OBGYN practices around the United States during COVID-19.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant, and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly-traded company, OTCQB:CCEL. For more information, please visit http://www.cryo-cell.com. For a complete list of references, visit http://www.cryo-cell.com/references.

Forward-Looking Statement Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company, which include future medical and research developments. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

Share article on social media or email:

More:
Cryo-Cell to Donate 50,000 Face Masks to OBGYN Practices and Patients Around the Country Amidst COVID-19 - PR Web

Coronavirus: Abu Dhabi invests Dh3.6m in new technology to boost Covid-19 fight – The National

By Stem Cell Doctors

Pioneering scientists in Abu Dhabi have unveiled new cutting-edge technology which is set to provide vital support to patients battling Covid-19.

The Abu Dhabi Stem Cell Centre (ADSCC) has invested Dh3.6 million on a Helios Mass Cytometer, a state-of-the-art tool which experts say will help bolster the bodys defence against the virus.

The cytometer, the only one of its kind in the Middle East, will enable scientists at the centre to quickly and accurately profile individual human cells, allowing them to study and monitor a patients immune response to the virus.

"With this tool, the ADSCC can study clinical outcomes and changes in inflammatory or immune function from blood samples of Covid-19 patients, an ADSCC spokesperson said.

"This will allow us to address some of the pressing questions that remain unanswered regarding Covid-19.

Staff at the centre are currently receiving training on the operation of the new machine, which they have affectionately dubbed ''The Lamborghini''.

Scientists leading efforts to stem the spread of Covid-19 are seeking to assess whether those most at risk of severe symptoms can be identified early, what interventions can reduce its severity and what vaccines will prove most effective in staving off the virus.

The centre recently introduced a new therapy to treat the effects of Covid-19, which has proved fruitful for a number of patients with severe symptoms.

It involves isolating then activating stem cells taken from the patient's blood before they are nebulised into a fine mist so they can be inhaled into the lungs.

The first UAE patient to recover from Covid-19 after undergoing the stem-cell therapy told The National last month of his gruelling journey to "full health" after being placed in a coma to stop his organs shutting down.

Members of a Palestinian team called ''Bella Ciao", dressed as actors of "La Casa de Papel (Money Heist)" series, perform in Gaza City. Reuters

A man takes a selfie with a member of ''Bella Ciao". Reuters

Iraqi medical specialists take part in a testing process for the coronavirus in Baghdad's Karada district. EPA

Iraqi medical specialists take a blood sample from a man for a coronavirus test in Baghdad's Karada district. EPA

Customers sit at a cafe in Damascus, Syria. EPA

Customers sit on the terrace of a cafe in Damascus, Syria. EPA

Iranians walk past in a street, in Tehran. EPA

A Muslim performs the Friday prayers inside the Al-Rajhi Mosque, Riyadh, Saudi Arabia. Reuters

Muslims perform the Friday prayers inside the Al-Rajhi Mosque, Riyadh, Saudi Arabia. Reuters

Yemenis walk past historic buildings in the old quarter of Sanaa. EPA

A worker disinfects a shopper's hands before they enter a mall in Sanaa, Yemen. AP Photo

Jordanians perform their first Friday prayers since the start of the pandemic at a mosque in Amman. EPA

Believers gather in a mosque in Tunis. Tunisia. AP Photo

A drone with a thermal camera flies over Habib Burgiba Street in Tunis, Tunisia. EPA

Mohamed Hawas Al Sadid, CEO of Ambulatory Healthcare Services, at the the new Covid-19 Prime Assessment Centre at ADNEC, Abu Dhabi. Victor Besa

Covid-19 positive residents in the waiting room at the new Prime Assessment Center at ADNEC, Abu Dhabi. Victor Besa

Abdullahi Rodhile, 50, from Somalia, contracted the virus on March 30 and, because of an existing heart condition, his health deteriorated quickly.

The virus attacked his kidneys and lungs so badly that doctors rushed him into the intensive care unit at Sheikh Khalifa Medical City in Abu Dhabi and put him in an induced coma for 20 days.

I was brought back to life. I was dead and now I am alive, said Mr Rodhile, who works as a cargo clerk.

I have never been better. Thank God."

He spent 40 days in intensive care but only after he started the stem cell therapy did his lungs begin to improve slightly.

Mr Rodhile eventually healed enough to gradually awaken from the coma.

Scientists at Abu Dhabi Stem Cell Centre are continuing to harness latest technologies in order to aid patients in ill health.

The centre announced on Saturday it is to begin offering Minimal Residual Disease tests for cancer patients a first in the UAE.

The highly specialised test allows physicians to spot residual, potentially-resistant cells that can lead to a relapse in patients. Currently such a test is not available in the Emirates and cancer patients have to travel abroad to be tested because the test requires the use of a fresh sample to be accurate.

Updated: June 6, 2020 02:26 PM

Originally posted here:
Coronavirus: Abu Dhabi invests Dh3.6m in new technology to boost Covid-19 fight - The National

Global Stem Cells Market 2020 (COVID-19) Impact Analysis: Business Trends, Growth Insight, Statistics And Forecast to 2025 – Surfacing Magazine

By Embryonic Stem Cells

Global Stem Cells Market Growth (Status and Outlook) 2020-2025 published by MarketandResearch.biz presents immense clarity on the market size, share, and growth rate across different regions. The report is a comprehensive representation of the global Stem Cells market area through research, development, and analysis of information collected from different sources. The report covers the present scenario, the growth prospects, and enlists several important factors related to the market. It also covers the product contributions, revenue segmentation, and business overview of the leading players in the market. In the present day, the market is experiencing a massive growth velocity. The document offers an assessment of future trends and future changes in the market in 2020.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/137924

Report Offerings:

The data regarding the financial dynamic, business ups and downs, product demands, product sales, global market statistics, market growth enhancers, and others are delivered with an in-depth format. Then it incorporates key aspects related to the global Stem Cells industry driving factors, opportunities, challenges, market threats, restraints, new product launch, geographical analysis, and competitive tactics designed by key players in the market. Later on, the report features capital requirements, region classes, application, sales, and earnings, analysis on market competition, regional analysis, and market demand. It contains segmentation based on the type of product, application of the product, and the key geographical region supplying the product.

Key companies are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Below mentioned is the list of few companies engaged in the market: CCBC, Vcanbio, Beikebiotech, Boyalife.

This report studies the global market analyzes and researches the development status and forecast in Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries).

Market analysis by type: Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Market analysis by application: Diseases Therapy, Healthcare,

Moreover, the report includes an analysis of the Stem Cells consumption of each region studied in the report on the basis of country, type, and application. There are different players of the global market profiled in this section of the report. Additionally, all of the players are analyzed considering their recent developments, products, revenue, and company details. Later, production and production value estimates by type, estimates of key producers, and production and production volume estimates by region added in the research report.

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/137924/global-stem-cells-market-growth-status-and-outlook-2020-2025

All The Segments In This Report Are Structured On The Basis of The Following:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketandresearch.bizWeb: http://www.marketandresearch.biz

Read more from the original source:
Global Stem Cells Market 2020 (COVID-19) Impact Analysis: Business Trends, Growth Insight, Statistics And Forecast to 2025 - Surfacing Magazine

Sales Revenue of Adipose Tissue-derived Stem Cells to Increase in Coming 10 years on Back of Rapid Adoption Across Major Industries Medic Report -…

By Embryonic Stem Cells

Adipose tissue is rich in multi potent stem cells that have the capability to differentiate into a number of cell types including adipocytes, osteocytes, chondrocytes and others, in vitro. These Adipose Tissue-derived Stem Cells are used for a number of applications including stem cell differentiation studies, regenerative medicine, cell therapy, tissue engineering and development of induced pluripotent stem cell lineage. Adult stem cells such as the Adipose Tissue-derived Stem Cells have a very good potential for regenerative medicine. The Adipose Tissue-derived Stem Cells show higher yields compared with other stem cell sources. Some of the regenerative medicine applications using Adipose Tissue-derived Stem Cells include skin, bone and cartilage regeneration.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/25831

Although, Adipose Tissue-derived Stem Cells have the ability to differentiate into different cell types in vitro, unlike the embryonic stem cells they lack the ability to differentiate into all types of organs and tissues of the body. Derivation of stem cells from adipose tissue have a number of advantages including that fat tissue contain 100 to 1000 times more mesenchymal stem cells than the bone marrow. Furthermore the method of collection of fat tissue is relatively easier and is less invasive than that of bone marrow collection. Although Adipose Tissue-derived Stem Cells have a potential to be used in cell-based therapy, there are a number of challenges the Adipose Tissue-derived Stem Cells market has to face. Some of the challenge include the safety issue for the clinical use of Adipose Tissue-derived Stem Cells, development and differentiation of the cells, delivery of the cells in vivo and immune response after the transplant.

The global Adipose Tissue-derived Stem Cells market is segmented based on product type and end user. Based on product type the Adipose Tissue-derived Stem Cells can be categorized into cell line and reagent & kits. Cell line can be further classified based on the source of the adipose tissue such as human and rodents. Based on reagents the Adipose Tissue-derived Stem Cells market is further classified as media & sera and kits. Based on application the Adipose Tissue-derived Stem Cells market is classified into regenerative medicine, cell therapy, tissue engineering, and other applications such as cell differentiation studies and other similar research. End users of Adipose Tissue-derived Stem Cells market are biotechnology companies and academic and research institutes.

The Global Adipose Tissue-derived Stem Cells market is classified on the basis of product type, end user and region:

Based on the Product Type, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the application, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the end user, Adipose Tissue-derived Stem Cells market is segment as below:

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/25831

Growing research activities using stem cells along with the growth of regenerative medicine and cell therapy the global Adipose Tissue-derived Stem Cells market is set to expand considerably during the forecast period. However, ethical concerns and stringent regulations may hinder the growth of the global Adipose Tissue-derived Stem Cells market.

On the basis of geography, global Adipose Tissue-derived Stem Cells market is segmented into six major regions that include North America, Latin America, Europe, Asia-Pacific excluding China, China and Middle East & Africa. North America is expected to be the most lucrative Adipose Tissue-derived Stem Cells market owing to increased research activity of stem cells. Furthermore government support for regenerative and stem cell based studies along with cell therapy studies is driving the growth of the Adipose Tissue-derived Stem Cells market in the region. Changing government regulations in china is supporting the research activity that supports the growth of the adipose tissue-derived stem cell market in the region at a considerable rate.

Key participants operating in the Adipose Tissue-derived Stem Cells market are: Lonza, ThermoFisher Scientific, Celprogen, Inc, American CryoStem, Rexgenero Ltd, iXCells Biotechnologies, Merck KGaA, Lifeline Cell Technology, and others.

Follow this link:
Sales Revenue of Adipose Tissue-derived Stem Cells to Increase in Coming 10 years on Back of Rapid Adoption Across Major Industries Medic Report -...

Stem Cell Therapy Designed To Treat Severely Ill Coronavirus Patients Being Tested In Maryland – CBS Baltimore

By Stem Cell Treatment

BALTIMORE (WJZ) A stem cell therapy trial for the most critically ill coronavirus patients is underway in Maryland.

Researchers at the University of Maryland School of Medicine are trying to save the maximum number of patients who are significantly sickened by the virus and reduce the mortality rate.

Thanks to a sponsorship by Australian regenerative medicine company Mesoblast, the stem cell therapy trial is underway at several sites across the U.S., including in Maryland.

The therapy involves 300 people hospitalized with COVID-19 with moderate to severe acute respiratory distress syndrome.

These are patients that are intubated, requiring great support for their lung function, Dr. Sunjay Kaushal with the University of Maryland said.

CORONAVIRUS RESOURCES:

COVID-19 patients often become very ill from an escalated immune response referred to as a cytokine storm, which creates high levels of inflammation that can be fatal. The experimental stem cell therapy called remestemcel-L, which has been developed for various inflammatory conditions like what is being seen with the coronavirus, aims to block or mitigate that response, Kaushal said.

Were trying to extrapolate from what they have been shown to be efficacious in trying to treat before and trying to use that type of therapy now for COVID-19 patients, he said.

Once the final results from the trial are available, which could take between six and eight months, researchers hope to reach even more patients.

Were excited, weve seen some early signs that these cells may be efficacious, Kaushal said.

Ultimately, their hope is to provide a new treatment for those suffering from the worst cases of COVID-19.

Were hoping we can save a lot of patients lives, Kaushal said.

For the latest information on coronavirus go to the Maryland Health Departments website or call 211. You can find all of WJZs coverage on coronavirus in Maryland here.

Read the rest here:
Stem Cell Therapy Designed To Treat Severely Ill Coronavirus Patients Being Tested In Maryland - CBS Baltimore

→←